Skip to content
2000
Volume 32, Issue 4
  • ISSN: 1381-6128
  • E-ISSN: 1873-4286

Abstract

Melanoma brain metastases (MBM) are associated with poor prognosis and remain a significant challenge in oncology. In recent years, significant progress has been made in understanding the molecular mechanisms underlying MBM. Advances in targeted therapies, immunotherapies, and stereotactic radiosurgery (SRS) have significantly improved patient survival. This study presents an overview of the current landscape of treatment approaches and emerging modalities for MBM treatment, highlighting recent advancements and future directions for research and clinical practice.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cpd/10.2174/0113816128340742250118150157
2025-02-27
2026-01-31

  • From This Site

    /content/journals/cpd/10.2174/0113816128340742250118150157
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. SiegelR.L. GiaquintoA.N. JemalA. Cancer statistics, 2024.CA Cancer J. Clin.2024741124910.3322/caac.2182038230766
     [Google Scholar]
  2. AjithkumarT. ParkinsonC. FifeK. CorrieP. JefferiesS. Evolving treatment options for melanoma brain metastases.Lancet Oncol.20151613e486e49710.1016/S1470‑2045(15)00141‑226433822
     [Google Scholar]
  3. CagneyD.N. MartinA.M. CatalanoP.J. RedigA.J. LinN.U. LeeE.Q. WenP.Y. DunnI.F. BiW.L. WeissS.E. Haas-KoganD.A. AlexanderB.M. AizerA.A. Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: A population-based study.Neuro-oncol.201719111511152110.1093/neuonc/nox07728444227
     [Google Scholar]
  4. AeS CjN DbE Diagnosis and treatment of melanoma brain metastasis: A literature review.Cancer Control200916324825310.1177/107327480901600307
     [Google Scholar]
  5. SaltarinF. WegmüllerA. BejaranoL. IldizE.S. ZwickyP. VianinA. SpadinF. SoukupK. WischnewskiV. EngelhardtB. DeutschU. J MarquesI. FrenzM. JoyceJ.A. LyckR. Compromised blood-brain barrier junctions enhance melanoma cell intercalation and extravasation.Cancers20231520507110.3390/cancers1520507137894438
     [Google Scholar]
  6. BugaA.M. DoceaA. AlbuC. MalinR. BranisteanuD. IanosiG. IanosiS. IordacheA. CalinaD. Molecular and cellular stratagem of brain metastases associated with melanoma (Review).Oncol. Lett.20191754170417510.3892/ol.2019.993330944612
     [Google Scholar]
  7. AsciertoP.A. KirkwoodJ.M. GrobJ.J. SimeoneE. GrimaldiA.M. MaioM. PalmieriG. TestoriA. MarincolaF.M. MozzilloN. The role of BRAF V600 mutation in melanoma.J. Transl. Med.20121018510.1186/1479‑5876‑10‑8522554099
     [Google Scholar]
  8. KraftT. GrützmannK. MeinhardtM. MeierF. WestphalD. SeifertM. Personalized identification and characterization of genome-wide gene expression differences between patient- matched intracranial and extracranial melanoma metastasis pairs.Acta Neuropathol. Commun.20241216710.1186/s40478‑024‑01764‑538671536
     [Google Scholar]
  9. MargolinK. ErnstoffM.S. HamidO. LawrenceD. McDermottD. PuzanovI. WolchokJ.D. ClarkJ.I. SznolM. LoganT.F. RichardsJ. MichenerT. BaloghA. HellerK.N. HodiF.S. Ipilimumab in patients with melanoma and brain metastases: An open-label, phase 2 trial.Lancet Oncol.201213545946510.1016/S1470‑2045(12)70090‑622456429
     [Google Scholar]
  10. LongG.V. AtkinsonV. LoS. SandhuS. GuminskiA.D. BrownM.P. WilmottJ.S. EdwardsJ. GonzalezM. ScolyerR.A. MenziesA.M. McArthurG.A. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: A multicentre randomised phase 2 study.Lancet Oncol.201819567268110.1016/S1470‑2045(18)30139‑629602646
     [Google Scholar]
  11. LongG.V. AtkinsonV. LoS. GuminskiA.D. SandhuS.K. BrownM.P. GonzalezM. ScolyerR.A. EmmettL. McArthurG.A. MenziesA.M. Five-year overall survival from the anti-PD1 brain collaboration (ABC Study): Randomized phase 2 study of nivolumab (nivo) or nivo+ipilimumab (ipi) in patients (pts) with melanoma brain metastases (mets).J. Clin. Oncol.20213915_supplSuppl.9508950810.1200/JCO.2021.39.15_suppl.9508
     [Google Scholar]
  12. TawbiH.A. ForsythP.A. HodiF.S. AlgaziA.P. HamidO. LaoC.D. MoschosS.J. AtkinsM.B. LewisK. PostowM.A. ThomasR.P. GlaspyJ. JangS. KhushalaniN.I. PavlickA.C. ErnstoffM.S. ReardonD.A. KudchadkarR. TarhiniA. ChungC. RitchingsC. DuraniP. AskelsonM. PuzanovI. MargolinK.A. Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study.Lancet Oncol.202122121692170410.1016/S1470‑2045(21)00545‑334774225
     [Google Scholar]
  13. Di GiacomoA.M. Chiarion-SileniV. Del VecchioM. FerrucciP.F. GuidaM. QuaglinoP. GuidoboniM. MarchettiP. CutaiaO. AmatoG. CovreA. CameriniR. CalabròL. ValenteM. GiannarelliD. MandalàM. MaioM. Primary analysis and 4-year follow-up of the phase iii nibit-m2 trial in melanoma patients with brain metastases.Clin. Cancer Res.202127174737474510.1158/1078‑0432.CCR‑21‑104634112708
     [Google Scholar]
  14. Di GiacomoA.M. Chiarion-SileniV. Del VecchioM. FerrucciP.F. GuidaM. QuaglinoP. GuidoboniM. MarchettiP. SimonettiE. SantangeloF. AmatoG. CovreA. CameriniR. ValenteM. MandalàM. GiannarelliD. CalabròL. MaioM. Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial.Eur. J. Cancer202419911353110.1016/j.ejca.2024.11353138271746
     [Google Scholar]
  15. YangM. CuiM. SunY. LiuS. JiangW. Mechanisms, combination therapy, and biomarkers in cancer immunotherapy resistance.Cell Commun. Signal.202422133810.1186/s12964‑024‑01711‑w38898505
     [Google Scholar]
  16. LongG.V. TrefzerU. DaviesM.A. KeffordR.F. AsciertoP.A. ChapmanP.B. PuzanovI. HauschildA. RobertC. AlgaziA. MortierL. TawbiH. WilhelmT. ZimmerL. SwitzkyJ. SwannS. MartinA.M. GuckertM. GoodmanV. StreitM. KirkwoodJ.M. SchadendorfD. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): A multicentre, open-label, phase 2 trial.Lancet Oncol.201213111087109510.1016/S1470‑2045(12)70431‑X23051966
     [Google Scholar]
  17. DaviesM.A. SaiagP. RobertC. GrobJ.J. FlahertyK.T. AranceA. Chiarion-SileniV. ThomasL. LesimpleT. MortierL. MoschosS.J. HoggD. Márquez-RodasI. Del VecchioM. LebbéC. MeyerN. ZhangY. HuangY. MookerjeeB. LongG.V. Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): A multicentre, multicohort, open-label, phase 2 trial.Lancet Oncol.201718786387310.1016/S1470‑2045(17)30429‑128592387
     [Google Scholar]
  18. WilmottJ.S. TawbiH. EnghJ.A. AmankulorN.M. ShivalingamB. BanerjeeH. VergaraI.A. LeeH. JohanssonP.A. FergusonP.M. SaiagP. RobertC. GrobJ.J. ButterfieldL.H. ScolyerR.A. KirkwoodJ.M. LongG.V. DaviesM.A. Clinical features associated with outcomes and biomarker analysis of dabrafenib plus trametinib treatment in patients with braf-mutant melanoma brain metastases.Clin. Cancer Res.202329352153110.1158/1078‑0432.CCR‑22‑258136477181
     [Google Scholar]
  19. MenziesA.M. LongG.V. KohnA. TawbiH. WeberJ. FlahertyK. McArthurG.A. AsciertoP.A. PflugerY. LewisK. TsaiK.K. HamidO. PrenenH. FeinL. WangE. GuenzelC. ZhangF. KlehaJ.F. di PietroA. DaviesM.A. POLARIS: A phase 2 trial of encorafenib plus binimetinib evaluating high-dose and standard-dose regimens in patients with BRAF V600-mutant melanoma with brain metastasis.Neurooncol. Adv.202461vdae03310.1093/noajnl/vdae03338725995
     [Google Scholar]
  20. AlbrechtL.J. DimitriouF. GroverP. HasselJ.C. ErdmannM. ForschnerA. JohnsonD.B. VáraljaiR. LoddeG. PlackeJ.M. KreftingF. ZarembaA. UgurelS. RoeschA. SchulzC. BerkingC. PöttgenC. MenziesA.M. LongG.V. DummerR. LivingstoneE. SchadendorfD. ZimmerL. Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma.Eur. J. Cancer202420211397610.1016/j.ejca.2024.11397638484692
     [Google Scholar]
  21. MinnitiG. D’AngelilloR.M. ScaringiC. TrodellaL.E. ClarkeE. MatteucciP. OstiM.F. RamellaS. EnriciR.M. TrodellaL. Fractionated stereotactic radiosurgery for patients with brain metastases.J. Neurooncol.2014117229530110.1007/s11060‑014‑1388‑324488446
     [Google Scholar]
  22. ShawE ScottC SouhamiL Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: Final report of RTOG protocol 90-05.Int. J. Radiat. Oncol. Biol. Phys.200047229129810.1016/S0360‑3016(99)00507‑6
     [Google Scholar]
  23. RishiA. YuH.H.M. Current treatment of melanoma brain metastasis.Curr. Treat. Options Oncol.20202164510.1007/s11864‑020‑00733‑z32350685
     [Google Scholar]
  24. LiewD.N. KanoH. KondziolkaD. MathieuD. NiranjanA. FlickingerJ.C. KirkwoodJ.M. TarhiniA. MoschosS. LunsfordL.D. Outcome predictors of Gamma Knife surgery for melanoma brain metastases.J. Neurosurg.2011114376977910.3171/2010.5.JNS101420524829
     [Google Scholar]
  25. YamamotoM. KawabeT. SatoY. HiguchiY. NariaiT. WatanabeS. KasuyaH. Stereotactic radiosurgery for patients with multiple brain metastases: A case-matched study comparing treatment results for patients with 2–9 versus 10 or more tumors.J. Neurosurg.2014121Suppl. 2162510.3171/2014.8.GKS14142125434933
     [Google Scholar]
  26. SuskoM.S. GarciaM.A. MaL. NakamuraJ.L. RaleighD.R. FoghS. TheodosopoulosP. McDermottM. SneedP.K. BraunsteinS.E. Stereotactic radiosurgery to more than 10 brain metastases: Evidence to support the role of radiosurgery for ideal hippocampal sparing in the treatment of multiple brain metastases.World Neurosurg.2020135e174e18010.1016/j.wneu.2019.11.08931785436
     [Google Scholar]
  27. MahajanA. AhmedS. McAleerM.F. WeinbergJ.S. LiJ. BrownP. SettleS. PrabhuS.S. LangF.F. LevineN. McGovernS. SulmanE. McCutcheonI.E. AzeemS. CahillD. TatsuiC. HeimbergerA.B. FergusonS. GhiaA. DemonteF. RazaS. Guha-ThakurtaN. YangJ. SawayaR. HessK.R. RaoG. Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: A single-centre, randomised, controlled, phase 3 trial.Lancet Oncol.20171881040104810.1016/S1470‑2045(17)30414‑X28687375
     [Google Scholar]
  28. RedmondK.J. De SallesA.A.F. FariselliL. LevivierM. MaL. PaddickI. PollockB.E. RegisJ. SheehanJ. SuhJ. YomoS. SahgalA. Stereotactic radiosurgery for postoperative metastatic surgical cavities: A critical review and international stereotactic radiosurgery society (ISRS) practice guidelines.Int. J. Radiat. Oncol. Biol. Phys.20211111688010.1016/j.ijrobp.2021.04.01633891979
     [Google Scholar]
  29. MinnitiG. EspositoV. ClarkeE. ScaringiC. LanzettaG. SalvatiM. RacoA. BozzaoA. Maurizi EnriciR. Multidose stereotactic radiosurgery (9 Gy × 3) of the postoperative resection cavity for treatment of large brain metastases.Int. J. Radiat. Oncol. Biol. Phys.201386462362910.1016/j.ijrobp.2013.03.03723683828
     [Google Scholar]
  30. MinnitiG. ClarkeE. LanzettaG. OstiM.F. TrasimeniG. BozzaoA. RomanoA. EnriciR.M. Stereotactic radiosurgery for brain metastases: Analysis of outcome and risk of brain radionecrosis.Radiat. Oncol.2011614810.1186/1748‑717X‑6‑4821575163
     [Google Scholar]
  31. HongA.M. FogartyG.B. Dolven-JacobsenK. BurmeisterB.H. LoS.N. HayduL.E. VardyJ.L. NowakA.K. DhillonH.M. AhmedT. ShivalingamB. LongG.V. MenziesA.M. HrubyG. DrummondK.J. MandelC. MiddletonM.R. ReisseC.H. PatonE.J. SteelV. WilliamsN.C. ScolyerR.A. MortonR.L. ThompsonJ.F. Adjuvant whole-brain radiation therapy compared with observation after local treatment of melanoma brain metastases: A multicenter, randomized phase III trial.J. Clin. Oncol.201937333132314110.1200/JCO.19.0141431553661
     [Google Scholar]
  32. WangY. LiuZ.G. YuanH. DengW. LiJ. HuangY. KimB.Y.S. StoryM.D. JiangW. The reciprocity between radiotherapy and cancer immunotherapy.Clin. Cancer Res.20192561709171710.1158/1078‑0432.CCR‑18‑258130413527
     [Google Scholar]
  33. RatnayakeG. ReinwaldS. ShackletonM. MooreM. VoskoboynikM. RubenJ. van ZelmM.C. YuD. WardR. SmithR. HaydonA. SenthiS. Stereotactic radiation therapy combined with immunotherapy against metastatic melanoma: Long-term results of a phase 1 clinical trial.Int. J. Radiat. Oncol. Biol. Phys.2020108115015610.1016/j.ijrobp.2020.05.02232450331
     [Google Scholar]
  34. PostowM.A. CallahanM.K. BarkerC.A. YamadaY. YuanJ. KitanoS. MuZ. RasalanT. AdamowM. RitterE. SedrakC. JungbluthA.A. ChuaR. YangA.S. RomanR.A. RosnerS. BensonB. AllisonJ.P. LesokhinA.M. GnjaticS. WolchokJ.D. Immunologic correlates of the abscopal effect in a patient with melanoma.N. Engl. J. Med.20123661092593110.1056/NEJMoa111282422397654
     [Google Scholar]
  35. StamellE.F. WolchokJ.D. GnjaticS. LeeN.Y. BrownellI. The abscopal effect associated with a systemic anti-melanoma immune response.Int. J. Radiat. Oncol. Biol. Phys.201385229329510.1016/j.ijrobp.2012.03.01722560555
     [Google Scholar]
  36. SilkA.W. BassettiM.F. WestB.T. TsienC.I. LaoC.D. Ipilimumab and radiation therapy for melanoma brain metastases.Cancer Med.20132689990610.1002/cam4.14024403263
     [Google Scholar]
  37. LehrerE.J. PetersonJ. BrownP.D. SheehanJ.P. Quiñones-HinojosaA. ZaorskyN.G. TrifilettiD.M. Treatment of brain metastases with stereotactic radiosurgery and immune checkpoint inhibitors: An international meta-analysis of individual patient data.Radiother. Oncol.201913010411210.1016/j.radonc.2018.08.02530241791
     [Google Scholar]
  38. KiessAP WolchokJD BarkerCA Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: Safety profile and efficacy of combined treatment.Int. J. Radiat. Oncol. Biol. Phys.201592236837510.1016/j.ijrobp.2015.01.004
     [Google Scholar]
  39. HadiI. RoengvoraphojO. BodensohnR. HofmaierJ. NiyaziM. BelkaC. NachbichlerS.B. Stereotactic radiosurgery combined with targeted/ immunotherapy in patients with melanoma brain metastasis.Radiat. Oncol.20201513710.1186/s13014‑020‑1485‑832059731
     [Google Scholar]
  40. LiC. LiK. ZhongS. TangM. ShiX. BaoY. Which is the best treatment for melanoma brain metastases? A Bayesian network meta-analysis and systematic review.Crit. Rev. Oncol. Hematol.202419410422710.1016/j.critrevonc.2023.10422738220124
     [Google Scholar]
  41. Binimetinib encorafenib pembrolizumab +/​- stereotactic radiosurgery in BRAF V600 melanoma with brain metastasis (BEPCOME-MB).Patent NCT040740962024
  42. A study of oral IRAK-4 inhibitor CA-4948 in combination with pembrolizumab following stereotactic radiosurgery in patients with melanoma brain metastasesPatent NCT056693522024
  43. Anti-PD 1 brain collaboration + radiotherapy extension (ABC-X Study) (ABC-X).Patent NCT033401292024
  44. Immunotherapy or targeted therapy with or without stereotactic radiosurgery for patients with brain metastases from melanoma or non-small cell lung cancer (USZ-STRIKE).Patent NCT055226602024
/content/journals/cpd/10.2174/0113816128340742250118150157
Loading

  • Article Type:     Review Article
Keyword(s): brain metastases; immunotherapy; Melanoma; metastases; radiation therapy; targeted therapy

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test